GammaCore for Migraine

Overview
A prescription device, gammaCore is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of pain associated with migraine headaches in people aged 12 years and older. It is also authorized for the preventive treatment of migraines in the same age group. Eligibility for gammaCore requires a prescription from a licensed healthcare provider (HCP) and adherence to usage instructions as detailed by the manufacturer. 

An external vagus nerve stimulator, gammaCore delivers mild electrical stimulation to the vagus nerve via the skin on the neck. Scientists believe the device works by modulating nerve activity that contributes to the onset and intensity of migraine headaches. Each treatment lasts approximately two minutes and can be performed multiple times daily based on the prescribed regimen​​.

How do I take it?
Instructions for use specify that gammaCore should be applied to the neck for a two-minute stimulation session at the onset of migraine pain or as a preventive measure. For preventive use, individuals typically perform two consecutive stimulations on the same side of the neck in the morning within one hour of waking and again in the evening. For acute migraine pain, a session can be repeated if pain persists, as long as the maximum daily number of stimulations is not exceeded. Treatments can be applied on the same side of the neck or alternated to the opposite side based on user comfort. In all cases, conductive gel should be applied to the device's stimulation surfaces before each treatment. The device should always be used exactly as prescribed by a healthcare provider.

Side effects
Common side effects of gammaCore include application site discomfort, irritation, or discoloration; localized pain in the face, head, or neck area; muscle twitching or contractions in the neck or face; dizziness; and paresthesia (tingling or a sensation of “pins and needles”) at the application site. These side effects typically resolve once stimulation ends​​.

Rare but serious side effects may include voice changes, shortness of breath, or worsening of headache symptoms. People with active implantable medical devices (e.g., pacemakers), those with cardiovascular or neurological conditions, and pregnant individuals are advised not to use GammaCore.

For more information about this treatment, visit:

De Novo Classification Request for GammaCore Non-Invasive Vagus Nerve Stimulator — U.S. Food and Drug Administration

GammaCore Dosing Information — ElectroCore